Skip to content

Released Aug 12, 2024, before the open

10-Q filed Aug 12, 2024, 43 days after period end · 0001171843-24-004670

Q2 2024 · 10-Q
Revenue$850.00K— vs Q2 2023no prior Q1 2024 on file
Net Income-$13.08MN/M vs Q2 2023N/M vs Q1 2024
EPS, diluted—
Operating Income-$15,045,000N/M
Operating Cash Flowderived-$10,754,000N/M
Free Cash Flowderived-$10,754,000N/M
Margins · derived
Operating margin-1770.0%
Net margin-1538.4%

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Revenue$850.00K$0.00——
Net Income-$13.08M-$11.28M-$8.49M-$55.80M
EPS Diluted———-$1.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR